Related Experiment Video

Updated: Nov 29, 2025

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.2K

Primary refractory multiple myeloma - what role for high dose melphalan?

Sergio Giralt1

  • 1Department of Medicine, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, Medicine Weill Cornell Medical College, New York, NY, USA.

Leukemia & Lymphoma
|November 23, 2020
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.7K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.9K

Related Experiment Videos

Last Updated: Nov 29, 2025

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.2K
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.7K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K

Articles linked to this work by shared authors, journal, and citation graph.

Impact of Bridging Response on Outcomes after CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.

Transplantation and cellular therapy·2026

Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies.

Clinical lymphoma, myeloma & leukemia·2026

Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma.

Blood cancer journal·2026

Feasibility Study: Early Experiences With a Cancer Center's Virtual Expert Medical Opinion Program.

JCO oncology practice·2026

Atrial Fibrillation Following Autologous Stem Cell Transplantation in Multiple Myeloma: Incidence, Predictors, and Prognostic Impact.

JACC. CardioOncology·2026

Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up Doses.

JCO oncology practice·2025

Treatment inequity among older adults with newly diagnosed acute myeloid leukemia ineligible for intensive therapy.

Leukemia & lymphoma·2026

Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison.

Leukemia & lymphoma·2026

Pre- and post-transplant serum albumin levels and outcomes after allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia.

Leukemia & lymphoma·2026

Leukemia mortality analysis in the pediatric population in São Paulo state, Brazil, 2000-2019.

Leukemia & lymphoma·2026

Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.

Leukemia & lymphoma·2026

Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL.

Leukemia & lymphoma·2026

Clinical characteristics, surgical management, and outcomes of uterine smooth muscle tumours of uncertain malignant potential: a single-centre experience.

Przeglad menopauzalny = Menopause review·2026

BCR-ABL1 Transcript Variants in Chronic Myeloid Leukemia Patients in Africa: A Systematic Review.

Health science reports·2026

Classical Hodgkin Lymphoma Today.

Mediterranean journal of hematology and infectious diseases·2026

Jiedu Xiaoliu formula enhances progression-free survival and immune modulation in diffuse large B-cell lymphoma: a retrospective cohort study.

Frontiers in pharmacology·2026

LTF promotes central nervous system leukemia progression via neutrophil serine proteases.

Frontiers in pharmacology·2026

Case Report: refractory hemophagocytic lymphohistiocytosis progression despite complete metabolic response in a patient with stage IV extranodal NK/T-cell lymphoma: clinical observation of "tumor-immune dissociation" phenomenon.

Frontiers in immunology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us